Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]
News [3681]
Articles [22]
Editorials [1]
Conferences [135]
elearning [0]
ASH 2010: Zoledronic acid shows anticancer activity in multiple myeloma patients, as well as protecting bone health
ASH 2010: Zoledronic acid shows anticancer activity in multiple myeloma patients, as well as protecting bone health
ASH 2010: Mitoxantrone significantly better than Idarubicin at improving outcome for children with relapsed acute lymphoblastic leukaemia
ASH 2010: Mitoxantrone significantly better than Idarubicin at improving outcome for children with relapsed acute...
ASH 2010: New tool to predict complete remission or early death for acute myeloid leukaemia
ASH 2010: New tool to predict complete remission or early death for acute myeloid leukaemia
ASH 2010: Rituximab after allogeneic stem cell transplantation prevents chronic graft-versus-host disease
ASH 2010: Rituximab after allogeneic stem cell transplantation prevents chronic graft-versus-host disease
ASH 2010: Double cord blood transplant associated with better overall outcomes than single
ASH 2010: Double cord blood transplant associated with better overall outcomes than single
ASH 2010: Toxicity of allogeneic transplantation outweighs benefits in patients with standard-risk myeloma
ASH 2010: Toxicity of allogeneic transplantation outweighs benefits in patients with standard-risk myeloma
ASH 2010: No higher incidence of cancer associated with donation of blood stem cells and bone marrow
ASH 2010: No higher incidence of cancer associated with donation of blood stem cells and bone marrow
ASH 2010: Rituximab delays need for chemotherapy in follicular lymphoma
ASH 2010: Rituximab delays need for chemotherapy in follicular lymphoma
ASH 2010: Retuximab for mantle cell lymphoma: European Mantle Cell Lymphoma Network reports
ASH 2010: Retuximab for mantle cell lymphoma: European Mantle Cell Lymphoma Network reports
ASH 2010: Innovative antibody-drug conjugate offers new hope in relapsed or refractory Hodgkin lymphoma
ASH 2010: Innovative antibody-drug conjugate offers new hope in relapsed or refractory Hodgkin lymphoma

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation